TALAPORFIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C38H41N5O9
Molecular Weight	711.7602
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC1=C(C)C2=CC3=C(C=C)C(C)=C(N3)C=C4N=C([C@@H](CCC(O)=O)[C@@H]4C)C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C5NC(=CC1=N2)C(C)=C5C(O)=O

InChI

InChIKey=VSEIDZLLWQQJGK-WSUYNKMOSA-N

InChI=1S/C38H41N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52)/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-/t18-,22-,30-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C38H39N5O9
Molecular Weight	709.7444
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/20001435
Curator's Comment: description was created based on several sources, including http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229

Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT). Talaporfin is injected into tumors and other regret tissues where it accumulates. It’s activated with light emitting diodes (LED). It absorbs red light at 664-667 nm normally provided by a laser tuned to this wavelength. It was approved in Japan (in 2004) for PDT of lung cancer and glioma and marketed as Laserphyrin. Clinical and preclinical studies indicate that talaporfin sodium treatment may offer a powerful option to synergize current therapies, as well as an alternative monotherapy in treating cancer.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Lung cancer 69 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26888042	Primary		Approved 8429	Unknown Approved Use Unknown
Malignant glioma 10 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26888042	Primary		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effect of talaporfin sodium-mediated photodynamic therapy on cell death modalities in human glioblastoma T98G cells.	2014	25374373

Patents

Sample Use Guides

In Vivo Use Guide

single intravenous injection of talaporfin sodium (40 mg/m(2)) was administered 1 day before resection of the neoplasm

Route of Administration: Intravenous

In Vitro Use Guide

combination of 30 µg/mL NPe6 (talaporfin sodium) with 5 J/cm(2) laser is the best treatment condition for inducing an increase in apoptotic cells while keeping rate of necrotic cell death low

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:53:10 GMT 2023` Edited by `admin` on `Sat Dec 16 17:53:10 GMT 2023`
Record UNII	P4ROX5ELT2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALAPORFIN

Official Name

English

Talaporfin [WHO-DD]

Common Name

English

TALAPORFIN [MI]

Common Name

English

(2S)-2-((((7S,8S)-3-CARBOXYLATO-7-(2-CARBOXYLATOETHYL)-13-ETHENYL-18-ETHYL-2,8,12,17-TETRAMETHYL-7,8-DIHYDROPORPHYRIN-5-YL)ACETYL)AMINO)BUTANEDIOIC ACID

Common Name

English

talaporfin [INN]

Common Name

English

L-ASPARTIC ACID, N-(((7S,8S)-3-CARBOXY-7-(2-CARBOXYETHYL)-13-ETHENYL-18-ETHYL-7,8-DIHYDRO-2,8,12,17-TETRAMETHYL-21H,23H-PORPHIN-5-YL)ACETYL)-

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1420